Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe (P9-11.026)
To investigate bioequivalence, safety, and tolerability of efgartigimod administered subcutaneously (SC, coformulated with recombinant human hyaluronidase) via prefilled syringe (PFS) vs a vial administered via a separate syringe (V+S) in healthy participants.
Authors
- Tiffanie L. Hargraves (ORCID: https://orcid.org/0000-0001-8672-7849)
- Jan Noukens
- Koen Allosery
- C De Muynck
- Filip Borgions
Institutions
- Argenx (Belgium) (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210572
- Citations
- 1
- Primary Topic
- Toxin Mechanisms and Immunotoxins
- Type
- article
- Field-Weighted Citation Impact
- 0.80